Table 6 Indirect comparison (Bucher analysis) of IVT-AFL 2q8 versus dexamethasone 0.7 mg implants for 12-month safety outcomes

Macular edema

2 studies (n = 657)*

RR = 0.22 [0.03–1.67]

RR = 0.22 [0.03–1.64]

OR = 0.21 [0.03–1.69]

OR = 0.21 [0.03–1.70]

Reduced visual acuity

3 studies (n = 1123)**

RR = 0.64 [0.24–1.67]

RR = 0.64 [0.17–2.40]

OR = 0.61 [0.21–1.77]

OR = 0.61 [0.21–1.77]

Vitreous hemorrhage

3 studies (n = 1123)**

RR = 0.30 [0.07–1.39]

RR = 0.18 [0.02–1.65]

OR = 0.28 [0.06–1.38]

OR =0.16 [0.02–1.54]

Eye pain

3 studies (n = 1123)**

RR = 0.80 [0.29–2.21]

RR = 0.78 [0.27–2.21]

OR = 0.79 [0.26–2.38]

OR = 0.76 [0.24–2.38]

Increased intraocular pressure

3 studies (n = 1123)**

RR = 0.08 [0.02–0.42]

RR = 0.13 [0.01–1.79]

OR = 0.07 [0.01–0.37]

OR = 0.11 [0.01–1.54]

Cataract

3 studies (n = 1123)**

RR = 0.42 [0.13–1.39]

RR = 0.43 [0.12–1.63]

OR = 0.40 [0.11–1.40]

OR = 0.41 [0.10–1.64]